SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/100426"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/100426" > Is chemotherapy nec...

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.

Thürlimann, Beat (författare)
Price, Karen N (författare)
Gelber, Richard D (författare)
visa fler...
Holmberg, Stig B, 1946 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery
Crivellari, Diana (författare)
Colleoni, Marco (författare)
Collins, John (författare)
Forbes, John F (författare)
Castiglione-Gertsch, Monica (författare)
Coates, Alan S (författare)
Goldhirsch, Aron (författare)
Wallgren, Arne, 1940 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
visa färre...
 (creator_code:org_t)
 
visa fler...
 
 
 
visa färre...
2009
2009
Engelska.
Ingår i: Breast cancer research and treatment. - 1573-7217. ; 113:1, s. 137-44
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • INTRODUCTION: International Breast Cancer Study Group (IBCSG) Trial 11-93 is the largest trial evaluating the role of the addition of chemotherapy to ovarian function suppression/ablation (OFS) and tamoxifen in premenopausal patients with endocrine-responsive early breast cancer. METHODS: IBCSG Trial 11-93 is a randomized trial comparing four cycles of adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to OFS and 5 years of tamoxifen versus OFS and tamoxifen without chemotherapy in premenopausal patients with node-positive, endocrine-responsive early breast cancer. There were 174 patients randomized from May 1993 to November 1998. The trial was closed before the target accrual was reached due to low accrual rate. RESULTS: Patients randomized tended to have lower risk node-positive disease and the median age was 45. After 10 years median follow up, there remains no difference between the two randomized treatment groups for disease-free (hazard ratio=1.02 (0.57-1.83); P=0.94) or overall survival (hazard ratio=0.97 (0.44-2.16); P=0.94). CONCLUSION: This trial, although small, offers no evidence that AC chemotherapy provides additional disease control for premenopausal patients with lower-risk node-positive endocrine-responsive breast cancer who receive adequate adjuvant endocrine therapy. A large trial is needed to determine whether chemotherapy adds benefit to endocrine therapy for this population.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
drug therapy
mortality
Chemotherapy
Adjuvant
Cyclophosphamide
administration & dosage
Doxorubicin
administration & dosage
Epirubicin
administration & dosage
Female
Follow-Up Studies
Humans
Lymph Nodes
pathology
Lymphatic Metastasis
Middle Aged
Premenopause
Receptors
Estrogen
analysis
Receptors
Progesterone
analysis
Risk Assessment
Survival Analysis
Survivors
Tamoxifen
therapeutic use

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy